Ardelyx reports Q4 EPS 2c, consensus 0c
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2025
0mins
Should l Buy ARDX?
Q4 Revenue Performance: Ardelyx reported Q4 revenue of $116.13 million, surpassing the consensus estimate of $111.16 million, indicating strong year-over-year growth for its products IBSRELA and XPHOZAH.
Strategic Focus and Future Goals: CEO Mike Raab emphasized the company's commitment to growing its product lines, executing strategies for XPHOZAH, building a robust pipeline of medicines, and maintaining strong financial performance to meet unmet medical needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARDX
Wall Street analysts forecast ARDX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.780
Low
10.00
Averages
14.86
High
19.00
Current: 6.780
Low
10.00
Averages
14.86
High
19.00
About ARDX
Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical need. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. NHE3 is an antiporter expressed on the apical surface of the small and large intestines. Tenapanor is a minimally absorbed, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation. Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. In addition to commercializing IBSRELA and XPHOZAH, it is also developing a next-generation NHE3 inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ardelyx Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Ardelyx reported $93.4 million in total product revenues for Q1 2026, reflecting a 38% year-over-year increase, with IBSRELA contributing $70.1 million, indicating strong market performance and growth potential.
- Pipeline Expansion: The company initiated the ACCEL trial to evaluate IBSRELA for chronic idiopathic constipation, with top-line data expected in the second half of 2027, laying the groundwork for future product line expansion.
- Improved Financial Stability: The CFO highlighted Ardelyx's trajectory towards profitability and cash generation, reiterating 2026 revenue guidance for IBSRELA between $410 million and $430 million, showcasing the company's growing financial maturity.
- Leadership Updates: The addition of a new Chief Legal Officer and Chief Medical Officer signifies strategic adjustments in management, aimed at enhancing execution capabilities and market competitiveness to support future growth strategies.
See More
ARDELYX Reports Q1 EPS of -$0.15
- Market Overview: The stock market is experiencing fluctuations, with notable movements in key indices.
- Economic Indicators: Recent economic data suggests mixed signals regarding inflation and employment rates.
- Sector Performance: Technology and healthcare sectors are showing resilience, while energy stocks are facing challenges.
- Investor Sentiment: Overall investor sentiment remains cautious amid ongoing geopolitical tensions and economic uncertainty.
See More
Ardelyx Q1 Earnings Miss Expectations with Revenue Decline
- Disappointing Earnings: Ardelyx reported a Q1 GAAP EPS of -$0.15, missing expectations by $0.01, indicating ongoing pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company generated $70.1 million in revenue for the quarter, a 5.4% year-over-year decrease, significantly missing expectations by $22.51 million, reflecting weak market demand and intensified competition that may hinder future growth.
- IBSRELA Revenue Guidance: Ardelyx anticipates IBSRELA revenue between $410 million and $430 million, showcasing significant growth potential; however, heavy operational spending could impact overall profitability, necessitating a focus on cost control strategies.
- Market Reaction: Despite the disappointing earnings, Ardelyx gained some market attention due to insider purchases and a marketing deal with LPGA, indicating a proactive approach in strategic partnerships.
See More
Ardelyx CEO Michael Raab Executes Stock Sale
- Stock Sale Overview: Ardelyx CEO Michael Raab sold 41,666 shares of common stock on March 16, 2026, at approximately $5.84 per share, totaling around $243,000, representing 2.21% of his holdings, indicating a strategic liquidity management approach.
- Options Exercise Details: The transaction involved the exercise of 20,833 options at $0.99 per share, allowing Raab to realize part of his holdings and enhancing his future liquidity options, which is crucial for personal financial strategy.
- Strategic Leadership Changes: Ardelyx appointed Rajani Dinavahi as the new Chief Medical Officer, bringing over 20 years of biotechnology and clinical leadership experience, which may signal a shift in the company's clinical decision-making and trial strategies, warranting investor attention.
- Legal Risk Mitigation: A class action lawsuit filed by investors in 2024 regarding misrepresentation of intentions for a Medicare program was dropped, indicating a reduction in legal risks for Ardelyx, which could bolster market confidence and support stock performance.
See More
Ardelyx CEO Sells Shares for Approximately $243,000
- Sale Overview: Ardelyx CEO Michael Raab sold 41,666 shares of common stock on March 16, 2026, for approximately $243,329, reflecting a stable trading pattern under his 10b5-1 plan.
- Transaction Structure: The sale included the exercise of options for 20,833 shares, with the number sold matching the recent median transaction size, indicating consistency in Raab's trading activities without signs of intent change.
- Ownership Update: Post-transaction, Raab holds 1,816,448 shares directly and 25,364 shares indirectly, while retaining 374,168 stock options, demonstrating continued capacity for future equity compensation transactions.
- Market Outlook: Despite Ardelyx's stock declining 16.57% over the past five years, it has increased by 6.8% year-over-year, with analysts setting an average price target of $16.10, suggesting a potential upside of about 170%, making it an attractive prospect for investors.
See More
Ardelyx Appoints New Chief Medical Officer
- Executive Appointment: Ardelyx, Inc. has appointed Rajani Dinavahi as Chief Medical Officer, bringing over 20 years of healthcare and biotechnology experience, having previously served as CMO at Atara Biotherapeutics, which is expected to enhance the company's expertise and leadership.
- Market Reaction: Following the announcement, Ardelyx shares rose 1.25% in pre-market trading on Nasdaq to $6.06, reflecting investor confidence in the new executive and positive market expectations for the company's future.
- Industry Context: Dinavahi's extensive background and leadership experience in biopharmaceuticals may drive Ardelyx's strategic direction in research and clinical trials, strengthening its position in the highly competitive biopharmaceutical market.
- Future Outlook: With the new CMO's appointment, Ardelyx is likely to accelerate its product development, particularly in the treatment of kidney diseases, further enhancing its market competitiveness and innovation capabilities.
See More
Ardelyx Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Ardelyx reported $93.4 million in total product revenues for Q1 2026, reflecting a 38% year-over-year increase, with IBSRELA contributing $70.1 million, indicating strong market performance and growth potential.
- Pipeline Expansion: The company initiated the ACCEL trial to evaluate IBSRELA for chronic idiopathic constipation, with top-line data expected in the second half of 2027, laying the groundwork for future product line expansion.
- Improved Financial Stability: The CFO highlighted Ardelyx's trajectory towards profitability and cash generation, reiterating 2026 revenue guidance for IBSRELA between $410 million and $430 million, showcasing the company's growing financial maturity.
- Leadership Updates: The addition of a new Chief Legal Officer and Chief Medical Officer signifies strategic adjustments in management, aimed at enhancing execution capabilities and market competitiveness to support future growth strategies.
See More
ARDELYX Reports Q1 EPS of -$0.15
- Market Overview: The stock market is experiencing fluctuations, with notable movements in key indices.
- Economic Indicators: Recent economic data suggests mixed signals regarding inflation and employment rates.
- Sector Performance: Technology and healthcare sectors are showing resilience, while energy stocks are facing challenges.
- Investor Sentiment: Overall investor sentiment remains cautious amid ongoing geopolitical tensions and economic uncertainty.
See More
Ardelyx Q1 Earnings Miss Expectations with Revenue Decline
- Disappointing Earnings: Ardelyx reported a Q1 GAAP EPS of -$0.15, missing expectations by $0.01, indicating ongoing pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company generated $70.1 million in revenue for the quarter, a 5.4% year-over-year decrease, significantly missing expectations by $22.51 million, reflecting weak market demand and intensified competition that may hinder future growth.
- IBSRELA Revenue Guidance: Ardelyx anticipates IBSRELA revenue between $410 million and $430 million, showcasing significant growth potential; however, heavy operational spending could impact overall profitability, necessitating a focus on cost control strategies.
- Market Reaction: Despite the disappointing earnings, Ardelyx gained some market attention due to insider purchases and a marketing deal with LPGA, indicating a proactive approach in strategic partnerships.
See More
Ardelyx CEO Michael Raab Executes Stock Sale
- Stock Sale Overview: Ardelyx CEO Michael Raab sold 41,666 shares of common stock on March 16, 2026, at approximately $5.84 per share, totaling around $243,000, representing 2.21% of his holdings, indicating a strategic liquidity management approach.
- Options Exercise Details: The transaction involved the exercise of 20,833 options at $0.99 per share, allowing Raab to realize part of his holdings and enhancing his future liquidity options, which is crucial for personal financial strategy.
- Strategic Leadership Changes: Ardelyx appointed Rajani Dinavahi as the new Chief Medical Officer, bringing over 20 years of biotechnology and clinical leadership experience, which may signal a shift in the company's clinical decision-making and trial strategies, warranting investor attention.
- Legal Risk Mitigation: A class action lawsuit filed by investors in 2024 regarding misrepresentation of intentions for a Medicare program was dropped, indicating a reduction in legal risks for Ardelyx, which could bolster market confidence and support stock performance.
See More
Ardelyx CEO Sells Shares for Approximately $243,000
- Sale Overview: Ardelyx CEO Michael Raab sold 41,666 shares of common stock on March 16, 2026, for approximately $243,329, reflecting a stable trading pattern under his 10b5-1 plan.
- Transaction Structure: The sale included the exercise of options for 20,833 shares, with the number sold matching the recent median transaction size, indicating consistency in Raab's trading activities without signs of intent change.
- Ownership Update: Post-transaction, Raab holds 1,816,448 shares directly and 25,364 shares indirectly, while retaining 374,168 stock options, demonstrating continued capacity for future equity compensation transactions.
- Market Outlook: Despite Ardelyx's stock declining 16.57% over the past five years, it has increased by 6.8% year-over-year, with analysts setting an average price target of $16.10, suggesting a potential upside of about 170%, making it an attractive prospect for investors.
See More
Ardelyx Appoints New Chief Medical Officer
- Executive Appointment: Ardelyx, Inc. has appointed Rajani Dinavahi as Chief Medical Officer, bringing over 20 years of healthcare and biotechnology experience, having previously served as CMO at Atara Biotherapeutics, which is expected to enhance the company's expertise and leadership.
- Market Reaction: Following the announcement, Ardelyx shares rose 1.25% in pre-market trading on Nasdaq to $6.06, reflecting investor confidence in the new executive and positive market expectations for the company's future.
- Industry Context: Dinavahi's extensive background and leadership experience in biopharmaceuticals may drive Ardelyx's strategic direction in research and clinical trials, strengthening its position in the highly competitive biopharmaceutical market.
- Future Outlook: With the new CMO's appointment, Ardelyx is likely to accelerate its product development, particularly in the treatment of kidney diseases, further enhancing its market competitiveness and innovation capabilities.
See More
